Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.

Jackson, Alice; Jhund, Pardeep; Anand, Inder; Düngen, Hans-Dirk; Lam, Carolyn; Lefkowitz, Marty; Linssen, Gerard; Lund, Lars; Maggioni, Aldo; Pfeffer, Marc; Rouleau, Jean; Saraiva, Jose; Senni, Michele; Vardeny, Orly; Wijkman, Magnus; Yilmaz, MEHMET; Saito, Yoshihiko; Zile, Michael; Solomon, Scott; Mcmurray, John

doi:10.1093/eurheartj/ehab499

Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.

Copy For Citation

Jackson A. M., Jhund P. S., Anand I. S., Düngen H., Lam C. S. P., Lefkowitz M. P., ...More

European heart journal, vol.42, no.36, pp.3741-3752, 2021 (SCI-Expanded)

Publication Type: Article / Article
Volume: 42 Issue: 36
Publication Date: 2021
Doi Number: 10.1093/eurheartj/ehab499
Journal Name: European heart journal
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Page Numbers: pp.3741-3752
Keywords: Heart failure, Preserved ejection fraction, Sacubitril-valsartan, Blood pressure, DOUBLE-BLIND, BLOOD-PRESSURE, RECEPTOR, NEPRILYSIN, SPIRONOLACTONE, INHIBITOR, LCZ696, DOXAZOSIN, PLACEBO
Dokuz Eylül University Affiliated: Yes

Abstract

Aims Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension. We examined the effect of neprilysin inhibition on 'apparent resistant hypertension' in patients with HFpEF in the PARAGON-HF trial, which compared the effect of sacubitril-valsartan with valsartan.